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Abstract
Objective: To evaluate the effectiveness and tolerability of omega-3 polyunsaturated fatty acid
(PUFA) supplementation for treatment of trait anxiety among adolescent females with restric-
tive anorexia nervosa (AN).
Method: A pilot double-blind, placebo-controlled randomized trial of adolescent females with
AN (N = 24) entering Partial Hospitalization Program (PHP) from January 2015 to February
2016. Participants were randomized to four daily PUFA (2,120 mg eicosapentaenoic acid/600
mg docosohexaenoic acid) or placebo capsules for 12 weeks. A 9-item questionnaire of side
effect frequency assessed medication tolerability. The Beck Anxiety Inventory-Trait measured
anxiety at baseline, 6, and 12 weeks. Linear mixed models evaluated associations between ran-
domization group and study outcomes. Twenty-two and 18 participants completed 6 and
12 weeks of data collection, respectively.
Results: Medication side effect scores were low and were not significantly different between
randomization groups at Week 6 (p = .20) or 12 (p = .41). Mean trait anxiety score significantly
(p < .01) decreased from baseline to 12 weeks in both groups, and the rate of change over the
course of time did not differ between omega-3 PUFA and placebo groups (p = .55).
Conclusion: Omega-3 PUFA supplementation was well tolerated in adolescent females with
AN. Although power to detect differences was limited, we found no evidence that omega-3
PUFA benefited anxiety beyond nutritional restoration.
KEYWORDS
adolescent, anorexia nervosa, anxiety, fatty acids, omega-3, randomized controlled trial
1 | BACKGROUND
Treatment of anorexia nervosa (AN) is complicated by high rates of
co-morbid psychiatric diagnoses (Ulfvebrand, Birgegard, Norring,
Hogdahl, & von Hausswolff-Juhlin, 2015) and lack of effective
pharmacologic interventions (Flament, Bissada, & Spettigue, 2012).
Anxiety disorders in particular are commonly comorbid with AN
(Thornton, Dellava, Root, Lichtenstein, & Bulik, 2011). Perfection-
ism, rigidity, compulsivity, and trait anxiety are elevated among
individuals diagnosed with AN (Hildebrandt, Bacow, Markella, &
Loeb, 2012). Standard medication treatments for generalized
anxiety, such as selective serotonin reuptake inhibitors (SSRIs), are
generally ineffective in malnourished individuals with AN
(Haleem, 2012).
There has been scientific interest in the utilization of omega-3
polyunsaturated fatty acids (PUFA) as treatment for several mental
health disorders (Bozzatello, Brignolo, De Grandi, & Bellino, 2016).
Unlike SSRIs which require protein synthesis, omega-3 PUFA are
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hypothesized to alter brain phospholipid composition and enhance
membrane fluidity, suggesting efficacy regardless of nutritional status
(Carlezon Jr. et al., 2005).
Observational studies in adolescents with eating disorders have
documented associations between depressive symptoms, low self-
reported omega-3 PUFA consumption, and low omega-3 PUFA in
erythrocyte membranes. In a population-based cohort study of
female adolescents (n = 66), self-reported omega-3 and omega-6
fatty acid dietary intake were significantly inversely correlated with
eating disorder and depressive symptoms among those with an eat-
ing disorder (Allen et al., 2013). In an earlier study exploring erythro-
cyte membrane fatty acid composition among 217 adolescents with
eating disorders, lower proportions of omega-3 PUFA were similarly
found to increase odds of depression (Swenne, Rosling, Tengblad, &
Vessby, 2011).
Supplementation trials have shown mixed results regarding
omega-3 PUFA and anxiety. No omega-3 PUFA effects were
observed in patients with obsessive compulsive disorder taking
maximum doses of SSRIs (Fux, Benjamin, & Nemets, 2004).
Decreased anxiety was found in patients enrolled in a substance
abuse treatment program supplemented with omega-3 PUFA
(Buydens-Branchey, Branchey, & Hibbeln, 2008). Decreased test-
related anxiety symptoms were observed in a non-clinical sample of
medical students receiving omega-3 PUFA of similar composition to
the current study (Kiecolt-Glaser, Belury, Andridge, Malarkey, &
Glaser, 2011). Mixed results of previous trials may be due to utili-
zation of omega-3 PUFA of differing compositions in varying popu-
lations with different methodologies. Lack of standardization has
limited our understanding of the relationship between omega-3
PUFA and anxiety.
With regards to AN and anxiety specifically, Barbarich
et al. conducted a placebo-controlled randomized trial of nutritional
supplements, containing omega-3 PUFA composed of 600 mg doco-
sohexaenoic acid (DHA) and 180 mg of arachadonic acid daily, in
young adults (mean age 23.0  6.3 years) with AN receiving fluoxe-
tine. No significant differences in change in anxiety were evident
between those on and off supplements, but the study was underpow-
ered to examine these effects (Barbarich et al., 2004). To our knowl-
edge, there have been no systematic trials of omega-3 PUFA in
adolescents with AN. The objective of this pilot randomized, placebo-
controlled study was to evaluate the effectiveness and tolerability of
omega-3 PUFA supplementation for improvement in trait anxiety in
female adolescents with restrictive AN.
2 | METHODS
This double-blind, placebo-controlled, single center pilot study was
approved by Nationwide Children’s Hospital's (NCH) Institutional
Review Board and the U.S. Food and Drug Administration (IND
117431). It was registered at clinicaltrials.gov (NCT01933243). The
study population consisted of adolescent females aged 12–21
admitted into the NCH Eating Disorders Partial Hospitalization Pro-
gram (PHP) for treatment of AN, restrictive subtype, from January
2015 to February 2016. Diagnosis was made via clinical interviews
and consensus of the multidisciplinary team based on the Diagnos-
tic and Statistical Manual of Mental Disorders Fifth Edition
(American Psychiatric Association, 2013). Every patient was first
assessed by an Adolescent Medicine physician, a licensed dietitian,
and a trained eating disorder therapist. This assessment established
the preliminary diagnosis, which was then confirmed by the pro-
gram’s psychiatrist during intake visit, occurring ~48 hr prior to the
start of PHP.
Study exclusion criteria included: (1) inability to take pills, (2) co-
morbidmedical condition affecting appetite or weight (e.g., inflammatory
bowel disease), (3) co-morbid psychiatric diagnoses affecting appetite
and weight (e.g., bipolar disorder), (4) currently taking omega-3 PUFA
supplements, (5) unable to participate in the study for 12 consecutive
weeks. SSRI use was not an exclusionary criterion for enrollment; 21 of
the 24 participants were on an SSRI during the study.
Of 41 potential participants assessed prior to expiration of fund-
ing, 2 did not meet inclusion criteria, 15 declined to participate, and
24 enrolled and were randomized in a 1:1 ratio to either omega-3
PUFA supplements (Nordic Naturals® ProEPA™ Xtra, Watsonville,
CA) or placebo (Nordic Naturals®, Watsonville, CA), four capsules
orally daily for 12 weeks (Figure 1). A block randomization scheme
was electronically generated by NCH Investigational Drug Service
Pharmacy (IDS) to randomize participants into blocks of 8 (Suresh,
2011). After consent, study staff contacted IDS who then assigned
participants to a treatment arm sequentially from a prepared list.
Study staff were not involved with randomization and were unaware
of upcoming allocation. Participants, study staff, and statistician were
blinded to drug assignment.
The four omega-3 PUFA capsules provided a total daily dose of
2,120 mg eicosapentaenoic acid (EPA), 600 mg DHA, and 404 mg of
other omega-3 PUFA. This high EPA product was chosen based on
prior data supporting effectiveness for anxiety (Kiecolt-Glaser et al.,
2011). Supplements contained lemon essential oil to mask potential
fishy aftertaste. Placebo capsules were identical color, size, and flavor
but contained predominantly soybean oil (3,960 mg total daily dose)
and negligible omega-3 PUFA (40 mg total daily dose).
Study visits occurred at baseline, 6, and 12 weeks. Of 24 enrolled
participants, 22 completed 6 weeks of data collection, and 18 com-
pleted 12 weeks (Figure 1). Reasons for study non-completion
included: loss to follow-up (n = 4) and self-withdrew (n = 2).
Measures conducted at each study visit included the Beck Anxi-
ety Inventory-Trait (BAIT) (Kohn, Kantor, DeCicco, & Beck, 2008),
Center for Epidemiologic Studies Depression Scale (CES-D) (Radloff,
1991), and Eating Attitudes Test (EAT-26) (Garner, Olmsted, Bohr, &
Garfinkel, 1982). Data were captured electronically and stored within
REDCap™. Surveys were programmed to require a response for all
fields.
The BAIT is a 21-item self-report measure of trait anxiety severity
rated on a 4-point Likert scale (0 = rarely or never; 3 = almost always).
It has shown acceptable reliability and validity in an adolescent psychi-
atric inpatient population (Osman et al., 2002). BAIT scores over
26 indicate severe anxiety, scores 16–25 moderate anxiety, scores
8–15 mild anxiety, and scores 0–7 minimal anxiety.
The CES-D is a well-validated instrument for self-report of
depression symptoms (Radloff, 1991). The 20-item survey uses a
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4-point Likert scale indicating frequency of agreement with state-
ments (0 = rarely; 3 = most of the time) with a range of 0–60. A
score of 24 or higher in females is indicative of high depressive
symptoms.
Eating Attitudes Test (EAT-26) is a standardized measure of prev-
alent symptoms and concerns characteristic of eating disorders
(Garner et al., 1982). The scale consists of 26 items rated on a 6-point
scale. Subscales include dieting; bulimia and food preoccupation; and
oral control. Although the EAT-26 is not a diagnostic tool, scores ≥20
are indicative of a heightened risk of eating disorder diagnosis.
At follow-up visits, medication tolerability was assessed via self-
report of nine potential side effects (e.g., diarrhea, burping), scored on
a 5-point frequency scale (0 = never; 4 = very frequently). Total side
effect score ranged from 0 to 36. Higher scores indicated lower medi-
cation tolerability.
Chart review was conducted to obtain height and weight closest
in date to research visits. Height was assessed using a wall-mounted
stadiometer with participant in stocking feet; weight was measured
with a SECA digital scale with participant gowned and in stocking feet.
Height and weight were not assessed as part of the research protocol
as standard of care in the Eating Disorders Program includes regular
measurement of both.
2.1 | Statistical analyses
All randomized participants were included in the analyses, in their ini-
tially randomized group, regardless of protocol deviation or adherence
(McCoy, 2017). The primary outcome was change in trait anxiety
(BAIT score) over the course of time. Power analysis prior to study ini-
tiation determined that we would need 20 per group to have 75%
power to detect a presumed mean difference of 5 between groups
with a standard deviation of 6. Secondary outcomes included BMI,
medication tolerability, EAT-26, and CES-D scores.
Patient demographic and clinical characteristics were reported as
means (standard deviations) for continuous variables and frequencies
(percentages) for categorical variables. Differences in baseline charac-
teristics were compared between study groups using Student’s t and
chi-square tests.
Linear mixed models with random intercepts to account for
repeated measures were used to evaluate the primary and secondary
outcomes over time. Models included main effects for study group
and time and a group by time interaction term to test for group differ-
ences in rate of change over time. Model-based estimates were
reported as least square means (95% confidence intervals). Hypothesis
testing was conducted at an alpha of .05; p-values <.05 were
FIGURE 1 Participant flow diagram
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considered statistically significant. Analyses were conducted using
SAS version 9.4 (SAS Institute, Cary, NC).
3 | RESULTS
At baseline, the study groups (omega-3 PUFA vs. placebo) did not
differ in age, race, height, weight, BMI, EAT-26, or trait anxiety
score (Table 1). Amenorrhea was present in over 50% of
participants.
Overall, side effect scores were low, indicating good medication
tolerability (Table 2). Mean side effect scores were not significantly
different between randomization groups at Week 6 (p = .20) or
12 (p = .41). Mean side effect scores significantly decreased from
Week 6 to Week 12 for the omega-3 PUFA group (p = .02) but not
the placebo group (p = .15); however, rate of change over time did
not differ between groups (p = .54). No serious drug-related adverse
events occurred in either group.
There were no significant differences between groups at any
time point in measures of weight, eating disorder symptoms, or
depression (Table 2). For both groups, improvement in these
measures was evident over 12 weeks, that is, there was a
significant main effect of time for BMI, EAT-26, and depression in
the expected directions.
Mean trait anxiety score was higher in the omega-3 PUFA group
at each time point, with the difference between groups being signifi-
cant at 6 and 12 weeks (Table 2). Scores in the omega-3 PUFA group
indicated severe anxiety at baseline and mild anxiety at 12 weeks;
scores in the placebo group indicated moderate anxiety at baseline
and minimal anxiety at 12 weeks. Mean trait anxiety significantly
(p < .01) decreased from baseline to 12 weeks in both groups, and the
rate of change in trait anxiety over the course of the study did not
differ between the two study groups (p = .55).
4 | DISCUSSION
In this pilot randomized controlled trial, female adolescents in PHP for
restrictive AN found omega-3 supplementation tolerable. Reported
side effects were infrequent, decreased over time, and were similar
for omega-3 PUFA and placebo. Overall, no significant differences
were found in change in trait anxiety, depression, eating disorder
symptoms, and BMI over 12 weeks regardless of randomization
group. Our findings suggest that omega-3 PUFA supplementation
does not confer additional benefit beyond nutritional restoration for
adolescents initiating PHP.
Study power was limited by small sample size and mean differ-
ence between groups which was smaller than anticipated. Despite the
null finding, the high tolerability of omega-3 PUFA supplementation
may warrant further study, particularly in the outpatient treatment
setting. It is possible that potential beneficial effects of omega-3
PUFA were modest and lost in the known significant effects of inten-
sive nutritional rehabilitation experienced in PHP.
Other limitations include reliance on self-reported medication
adherence, no measurement of blinding success, and no follow-up on
participants after study completion. Given that our sample was
entirely female and that the threshold for PHP admission likely varies
by institution, our findings may not be generalizable to other
populations.
In conclusion, omega-3 PUFA supplementation was well tolerated
in a population of adolescent females with moderate to severe
AN. We found no evidence that omega-3 PUFA supplementation
TABLE 1 Baseline participant characteristics by study group
Characteristic Omega-3 PUFAa (n = 12) Placebo (n = 12) p value
Age (years), mean (SD) 15.0 (1.3) 14.4 (1.8) .34
Race, n (%) .24
White non-Hispanic 12 (100.0) 10 (83.3)
Black non-Hispanic 0 (0.0) 2 (16.7)
Height (cm), mean(SD) 164.3 (8.0) 162.1 (9.0) .54
Weight (kg), mean (SD) 52.8 (7.6) 49.5 (9.2) .35
Body mass index (kg/m2), mean (SD) 19.6 (2.0) 18.8 (2.1) .33
Reported maximum weight (lbs), mean (SD) 125.2 (11.6) 124.1 (36.6) .93
Reported minimum weight (lbs), mean (SD) 101.7 (13.7) 96.8 (22.8) .53
Recent weight loss (lbs/month), mean (SD) 4.0 (2.1) 6.1 (3.4) .08
Presence of amenorrhea, n (%) 7 (58.3) 6 (50.0) .58
Eating disorder symptoms score,b mean (SD)
Dieting 21.8 (11.4) 23.2 (12.0) .78
Bulimia 5.6 (3.9) 6.9 (4.3) .44
Oral control 10.3 (5.2) 11.3 (5.5) .65
Total 37.7 (19.2) 41.3 (20.7) .66
Trait anxiety,c mean (SD) 26.4 (10.0) 18.9 (10.3) .08
a Omega-3 polyunsaturated fatty acid supplementation with 2,120 mg eicosapentaenoic acid +600 mg docosohexaenoic acid daily.
b Measured by The Eating Attitudes Test (EAT-26).
c Measured by The Beck Anxiety Inventory-Trait (BAIT).
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provides additional benefit beyond nutritional restoration for patients
enrolled in PHP. Future study with larger sample sizes should focus
on patients in less intensive treatment programs, incorporate physio-
logical measures of compliance, and explore PUFA supplements of
varying composition for potential effectiveness.
ACKNOWLEDGMENTS
This study was supported by the Clinical and Translational Intramural
Funding Program at the Research Institute at Nationwide Children's
Hospital and the Center for Integrative Health and Wellness at The
Ohio State University. Additional support received from OSU CTSA,
Grant no. UL1TR001070. Drug (active and placebo) provided in kind
by Nordic Naturals®.
ORCID
Andrea E. Bonny https://orcid.org/0000-0001-5874-1942
REFERENCES
Allen, K. L., Mori, T. A., Beilin, L., Byrne, S. M., Hickling, S., & Oddy, W. H.
(2013). Dietary intake in population-based adolescents: Support for a
relationship between eating disorder symptoms, low fatty acid intake
and depressive symptoms. Journal of Human Nutrition and Dietetics,
26(5), 459–469. https://doi.org/10.1111/jhn.12024
American Psychiatric Association (Ed.). (2013). Diagnostic and statistical
manual of mental disorders (5th ed.). Arlington, VA: American Psychiat-
ric Publishing, Inc.
Barbarich, N. C., McConaha, C. W., Halmi, K. A., Gendall, K., Sunday, S. R.,
Gaskill, J., … Kaye, W. H. (2004). Use of nutritional supplements to
increase the efficacy of fluoxetine in the treatment of anorexia ner-
vosa. International Journal of Eating Disorders, 35(1), 10–15. https://doi.
org/10.1002/eat.10235
Bozzatello, P., Brignolo, E., De Grandi, E., & Bellino, S. (2016). Supplemen-
tation with omega-3 fatty acids in psychiatric disorders: A review of lit-
erature data. Journal of Clinical Medicine, 5(8), E67. https://doi.org/10.
3390/jcm5080067.
Buydens-Branchey, L., Branchey, M., & Hibbeln, J. R. (2008). Associations
between increases in plasma n-3 polyunsaturated fatty acids following
supplementation and decreases in anger and anxiety in substance
abusers. Progress in Neuro-Psychopharmacology and Biological Psychia-
try, 32(2), 568–575. https://doi.org/10.1016/j.pnpbp.2007.10.020





6 weeks 12 10
12 weeks 10 8
Measure Omega-3 PUFAa Placebo Cohen’s D p value
Least squares mean (95% CI) Least squares mean (95% CI) Effect size (95% CI)
Medication side effects scoreb .54c
Baseline n/a n/a n/a n/a
6 weeks 9.7 (6.1, 13.2) 6.2 (2.1, 10.3) 0.52 (−0.4, 1.4)d .20d
12 weeks 6.4 (2.7, 10.0) 4.1 (−0.1, 8.3) 0.50 (−0.4, 1.5)d .41d
Body mass index (kg/m2) .42c
Baseline 19.6 (18.3, 20.8) 18.8 (17.5, 20.0) 0.41 (−0.4, 1.2)d .34d
6 weeks 21.6 (20.3, 22.8) 20.4 (19.1, 21.7) 0.37 (−0.5, 1.2)d .19d
12 weeks 21.9 (20.7, 23.2) 20.6 (19.3, 21.8) 0.25 (−0.7, 1.2)d .13d
Total EAT scoree .21c
Baseline 37.7 (26.2, 49.2) 41.3 (29.8, 52.8) −0.18 (−1.0, 0.6)d .65d
6 weeks 26.9 (15.4, 38.4) 28.3 (16.2, 40.4) −0.07 (−0.9, 0.8)d .87d
12 weeks 23.2 (11.2, 35.2) 14.0 (1.2, 26.8) 0.51 (−0.4, 1.5)d .30d
Depression scoref .94c
Baseline 28.8 (24.3, 33.4) 25.1 (20.5, 29.6) 0.44 (−0.4, 1.3)d .25d
6 weeks 26.1 (21.5, 30.6) 22.0 (17.2, 26.9) 0.45 (−0.4, 1.3)d .23d
12 weeks 21.0 (16.2, 25.8) 16.2 (11.1, 21.3) 0.42 (−0.5, 1.4)d .18d
Trait anxiety scoreg .55c
Baseline 26.4 (20.7, 32.1) 18.9 (13.2, 24.6) 0.74 (−0.1, 1.6)d .07d
6 weeks 22.2 (16.5, 27.9) 11.0 (5.1, 17.0) 1.11 (0.2, 2.0)d .01d
12 weeks 15.4 (9.4, 21.3) 6.3 (0.0, 12.6) 0.99 (0.0, 2.0)d .04d
a Omega-3 polyunsaturated fatty acid supplementation with 2,120 mg eicosapentaenoic acid +600 mg docosohexaenoic acid daily.
b Measured by a 9-item questionnaire (score range 0–36) addressing frequency of potential side effects.
c Value for difference in rate of change (interaction effect between group and time).
d Value for between group difference.
e Measured by The Eating Attitudes Test (EAT-26).
f Measured by the Center for Epidemiologic Studies Depression Scale (CES-D).
g Measured by the Beck Anxiety Inventory-Trait (BAIT).
MANOS ET AL. 1371
Carlezon, W. A., Jr., Mague, S. D., Parow, A. M., Stoll, A. L., Cohen, B. M., &
Renshaw, P. F. (2005). Antidepressant-like effects of uridine and
omega-3 fatty acids are potentiated by combined treatment in rats.
Biological Psychiatry, 57(4), 343–350. https://doi.org/10.1016/j.
biopsych.2004.11.038
Flament,M. F., Bissada,H., & Spettigue,W. (2012). Evidence-based pharmaco-
therapy of eating disorders. International Journal of Neuropsychopharmacol-
ogy, 15(2), 189–207. https://doi.org/10.1017/S1461145711000381
Fux, M., Benjamin, J., & Nemets, B. (2004). A placebo-controlled
cross-over trial of adjunctive EPA in OCD. Journal of Psychiatric
Research, 38(3), 323–325. https://doi.org/10.1016/S0022-3956(03)
00077-3
Garner, D. M., Olmsted, M. P., Bohr, Y., & Garfinkel, P. E. (1982). The eat-
ing attitudes test: Psychometric features and clinical correlates. Psycho-
logical Medicine, 12(4), 871–878.
Haleem, D. J. (2012). Serotonin neurotransmission in anorexia nervosa.
Behavioural Pharmacology, 23(5–6), 478–495. https://doi.org/10.
1097/FBP.0b013e328357440d
Hildebrandt, T., Bacow, T., Markella, M., & Loeb, K. L. (2012). Anxiety in
anorexia nervosa and its management using family-based treatment.
European Eating Disorders Review, 20(1), e1–e16. https://doi.org/10.
1002/erv.1071
Kiecolt-Glaser, J. K., Belury, M. A., Andridge, R., Malarkey, W. B., &
Glaser, R. (2011). Omega-3 supplementation lowers inflammation and
anxiety in medical students: A randomized controlled trial. Brain,
Behavior and Immunity, 25(8), 1725–1734. https://doi.org/10.1016/j.
bbi.2011.07.229
Kohn, P. M., Kantor, L., DeCicco, T. L., & Beck, A. T. (2008). The Beck anxi-
ety inventory-trait (BAIT): A measure of dispositional anxiety not con-
taminated by dispositional depression. Journal of Personality Assessment,
90(5), 499–506. https://doi.org/10.1080/00223890802248844
McCoy, C. E. (2017). Understanding the intention-to-treat principle in ran-
domized controlled trials. Western Journal of Emergency Medicine, 18(6),
1075–1078. https://doi.org/10.5811/westjem.2017.8.35985
Osman, A., Hoffman, J., Barrios, F. X., Kopper, B. A., Breitenstein, J. L., &
Hahn, S. K. (2002). Factor structure, reliability, and validity of the Beck
anxiety inventory in adolescent psychiatric inpatients. Journal of Clinical
Psychology, 58(4), 443–456.
Radloff, L. S. (1991). The use of the Center for Epidemiologic Studies
Depression Scale in adolescents and young adults. Journal of Youth and
Adolescence, 20(2), 149–166. https://doi.org/10.1007/BF01537606
Suresh, K. (2011). An overview of randomization techniques: An unbiased
assessment of outcome in clinical research. Journal of Human Reproduc-
tive Sciences, 4(1), 8–11. https://doi.org/10.4103/0974-1208.82352
Swenne, I., Rosling, A., Tengblad, S., & Vessby, B. (2011). Omega-3 polyun-
saturated essential fatty acids are associated with depression in adoles-
cents with eating disorders and weight loss. Acta Paediatrica, 100(12),
1610–1615. https://doi.org/10.1111/j.1651-2227.2011.02400.x
Thornton, L. M., Dellava, J. E., Root, T. L., Lichtenstein, P., & Bulik, C. M.
(2011). Anorexia nervosa and generalized anxiety disorder: Further
explorations of the relation between anxiety and body mass index.
Journal of Anxiety Disorders, 25(5), 727–730. https://doi.org/10.1016/j.
janxdis.2011.03.010
Ulfvebrand, S., Birgegard, A., Norring, C., Hogdahl, L., & von
Hausswolff-Juhlin, Y. (2015). Psychiatric comorbidity in women and men
with eating disorders results from a large clinical database. Psychiatry
Research, 230(2), 294–299. https://doi.org/10.1016/j.psychres.2015.09.008
SUPPORTING INFORMATION
Additional supporting information may be found online in the Sup-
porting Information section at the end of the article.
How to cite this article: Manos BE, Bravender TD,
Harrison TM, et al. A pilot randomized controlled trial of
omega-3 fatty acid supplementation for the treatment of anxi-
ety in adolescents with anorexia nervosa. Int J Eat Disord.
2018;51:1367–1372. https://doi.org/10.1002/eat.22964
1372 MANOS ET AL.
